NVAX:NASDAQ
Novavax Inc
$10.20
arrow_downward
-0.10%(-0.010) 1D
$10.12
arrow_downward
-0.78% (-0.080)todayPre-market
Closed: Jun 3, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$10.14
High
$10.32
Low
$9.94
Mkt. cap
1.68B
Avg. vol.
5.57M
Volume
2.72K
52-wk high
$11.97
52-wk low
$6.13
EPS
-$0.58
Beta
2.45
Shares outstanding
164.44M
No. of employees
749
Open
$10.14
High
$10.32
Low
$9.94
Mkt. cap
1.68B
Avg. vol.
5.57M
Volume
2.72K
52-wk high
$11.97
52-wk low
$6.13
EPS
-$0.58
Beta
2.45
Shares outstanding
164.44M
No. of employees
749
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to NVAX in the past 3 months
Hold
Buy
2
Hold
1
Sell
2
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for NVAX in the last 3 months.
Highest
Current $10.20
$18.00 (+76.47%)
Average
$11.60 (+13.73%)
Lowest
$7.00 (-31.37%)
News stories
From sources across the web
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com
AI content may include mistakes. Learn more